Influence of Mineral Supplementation on the Results from Analysis of Flavonol Glycoside Content in *Ginkgo biloba* Dietary Supplements

Jae-Kyoo Lee¹, Ouk-Hee Kim¹, Bo-Kyung Jung¹, In-Soon Cho¹, Yun-Jung Lee¹, Hee-Jin Choi¹, Youn-Cheon Kim¹, Young-Hee Oh¹, Kweon Jung³, Seung-Hyeon Cha², and Keum-II Jang²

¹Department of Food and Drug, Seoul Government Research Institute of Public Health and Environment, Gyeonggi 02569, Korea
²Department of Food Science and Biotechnology, Chungbuk National University, Chungbuk 28644, Korea

**ABSTRACT:** Flavonoids are a major component of *Ginkgo biloba* extract (GBE). Several studies have investigated chelate formation and the redox reaction between flavonoids and metal ions; however, the effect of mineral supplements on the results from the analysis of the flavonol glycoside content in products containing GBE dietary supplement remains unknown. In this study, the effects of commonly used mineral supplements on the recovery of quercetin from GBE-containing dietary supplements were investigated using conventional methods of flavonol glycoside determination. Mineral supplements containing Zn (II), Mn (II), and Fe (II) did not affect quercetin recovery, whereas Cu (II) and Fe (III) significantly reduced recovery (P<0.05). Quercetin oxidation was prevented by adding an antioxidant to the diluent (extraction solvent). Among the tested synthetic antioxidants, tert-butyl hydroquinone (TBHQ) promoted the greatest increase in quercetin recovery. The flavonol glycoside content of commercially available GBE-containing dietary supplements was analyzed using a conventional diluent or a diluent containing 20 mg/mL TBHQ. The amount of quercetin recovered from products containing Cu (II) was found to decrease with increasing hydrolysis duration and the duration in the final test solution state using the conventional diluent, while the TBHQ-containing diluent yielded consistent quercetin contents (P<0.05). These findings suggest that quercetin, a major aglycone of GBE flavonol glycosides, can be oxidized by Cu (II) and Fe (III) during the analytical process and, therefore, the total flavonol glycoside content may be underestimated. The addition of TBHQ to the diluent can improve the accuracy and reproducibility of flavonol glycoside content analysis in GBE-containing dietary products supplemented with minerals.

**Keywords:** *Ginkgo biloba*, flavonol glycoside, quercetin, oxidation, TBHQ

**INTRODUCTION**

*Ginkgo biloba* is one of the oldest living tree species and is considered a “living fossil”; its natural habitat is in China, Japan, and Korea. In the 18th century, it was introduced into Europe and the United States, and has been cultivated as an ornamental tree and a medicinal plant (1,2). The leaves and seeds of *Ginkgo biloba* have been used in traditional Chinese medicine in the treatment of asthma, bronchitis, and fatigue for several years. Moreover, extracts of the leaves are used in treatment for cardiovascular diseases, allergies, tinnitus, peripheral arterial occlusive diseases, cerebral insufficiency, and dementias such as Alzheimer’s disease (3-12).

*Ginkgo biloba* extract (GBE) is used in dietary supplements in addition to medicine. In Korea, GBE can be used as a constituent of health/functional food (HFF), which is regulated by the HFF Act of Korea. The term HFF refers to food supplements containing nutrients or other substances in a concentrated form that have nutritional or physiological effects, the purpose of which are to supplement normal diet. The Ministry of Food and Drug Safety (MFDS) of Korea has approved claims that GBE-containing HFFs improve memory and blood circulation (13,14).

Two major bioactive compounds in GBE are flavonoids and terpene lactones; the flavonoids are present primarily as glycosides. Therefore, quality control of GBE has been standardized for these two components. GBE contains more than 20 flavonoid glycosides, most of which...
are derived from quercetin, kaempferol, and isorhamnetin (2,3,15). In several standardized protocols to evaluate the quality of Ginkgo leaf and its related products, the total flavonol glycoside content was calculated from the content of the three primary aglycones: quercetin, kaempferol, and isorhamnetin (14-18).

Several HFF products containing GBE manufactured and sold in Korea also contain minerals such as zinc, iron, and copper (19). Furthermore, flavonoids are known to form chelate complexes with metal ions, and these chelates are known to result in increased bioavailability of flavonols and metals (20). In addition, it has been reported that iron and copper promote quercetin oxidation under low pH and increasing temperatures (21-23). Therefore, the aglycones of flavonol glycosides can be determined after acid hydrolysis and heating (14,15,17,18,24), which represents an oxidizing condition for both metal ions and flavonol aglycones. If GBE products also contain mineral supplements such as iron and copper, quercetin oxidation may occur after hydrolysis, affecting the quantitative analysis of flavonol glycosides. However, the effect of mineral supplements on the results from the analysis of flavonol glycoside content in GBE-containing dietary supplement products is not yet known.

In the present study, the effect of mineral supplements on the analysis of flavonol glycosides and methods to suppress this effect were investigated.

MATERIALS AND METHODS

Materials
Absolute ethanol and methanol were purchased from Fisher Scientific Korea (Seoul, Korea). Hydrochloric acid (HCl; 35%) was purchased from Matsuneno Chemicals Ltd. (Osaka, Japan). Phosphoric acid (85%), iron (II) fumarate, and manganese (II) sulfate pentahydrate were purchased from Wako Pure Chemical Corporation (Tokyo, Japan). Iron (III) chloride hexahydrate, iron (II) sulfate heptahydrate, butylated hydroxytoluene (BHT) and ethylenediaminetetraacetic acid (EDTA) were purchased from Junsei Chemical (Tokyo, Japan). Copper (II) sulfate and zinc (II) oxide were purchased from Kanto Chemical (Tokyo, Japan). Zinc (II) gluconate hydrate and tert-butyl hydroquinone (TBHQ) were purchased from Alfa Aesar (Tewksbury, MA, USA). Butylated hydroxyanisole (BHA) and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich USA, respectively. Methanol of gradient grade for LC was purchased from Merck (Darmstadt, Germany). GBE dietary supplement product samples were purchased from online stores (Table 1).

Preparation of reagents
Diluent (extraction solvent): The diluent used was ethanol : water : hydrochloric acid (50:20:8, v/v/v) (14,16,17). For the preparation of approximately 780 mL diluent, 500 mL ethanol, and 200 mL deionized water were added into a 1 L bottle, before 80 mL HCl (35%) was added carefully and mixed thoroughly.

Mineral supplement solutions: Iron (III) chloride hexahydrate, iron (II) fumarate, iron (II) sulfate heptahydrate, copper (II) D-gluconate, copper (II) sulfate, manganese (II) sulfate pentahydrate, zinc (II) oxide, and zinc (II) gluconate hydrate were individually dissolved in the diluent to produce anhydrous solutions containing 10 mg/mL of each mineral supplement. These solutions were further diluted with the diluent as necessary.

Antioxidant solutions: The antioxidants TBHQ, BHT, BHA, PG, and EDTA were individually dissolved in the diluent to yield solutions of approximately 10 mg/mL each. Because EDTA and BHA were insoluble in the diluent, these were dissolved in a solution of water : hydrochloric acid (20:8, v/v) first, before ethanol was added to restore the composition of the diluent.

Diluent (extraction solvent) containing 20 mg/mL (w/v) TBHQ: This diluent was prepared by dissolving 15.6 g TBHQ in 780 mL diluent and mixing thoroughly.

Quercetin hydrate solution (reference material for quercetin recovery testing): To prepare this solution, 0.6 g quercetin hydrate was dissolved in 3 mL DMSO with sonication for complete dissolution, diluted using 50 mL diluent, and mixed thoroughly. This solution contained approximately 10 mg/mL quercetin.

Quercetin dihydrate, kaempferol, and isorhamnetin standard stock solutions (analytical standards to determine flavonol aglycone content): Quercetin dihydrate, kaempferol, and isorhamnetin analytical standards were dissolved in 2 mL DMSO and sonicated for 2 min to dissolve the solids. Solutions were diluted to 100 mL with methanol and mixed thoroughly. The amount of quercetin dihydrate converted to quercetin was calculated as [quercetin (mg) = quercetin dihydrate (mg) \times 302/338]. The stock solutions were diluted with methanol to construct a five-point calibration curve with concentrations ranging from 4.438 to 110.96 μg/mL for quercetin, 4.656 to 116.4 μg/mL for kaempferol, and 0.792 to 19.8 μg/mL for isorhamnetin. The standard solutions were stored at 4°C for up to 6 months, and equilibrated at room temperature before use.
Table 1. *Ginkgo biloba* dietary supplement products used in this study

| Sample No. | Serving size | Flavonol glycosides | Mineral supplements | Others | Type |
|------------|--------------|---------------------|---------------------|--------|------|
| 2017S_FG_1 | 310 mg       | 14.4 mg             | −                   | −      | Tablet |
| 2017S_FG_2 | 1,000 mg     | 28 mg               | Zinc 8.5 mg, Iron 6 mg, Manganese 3.5 mg, Copper 0.5 mg | −      | Tablet |
| 2017S_FG_3 | 1,000 mg     | 28 mg               | Zinc 10 mg, Iron 4.5 mg | −      | Tablet |
| 2017S_FG_4 | 500 mg       | 28.8 mg             | Zinc 4.25 mg, Ferric fumarate | −      | Tablet |
| 2017S_FG_5 | 700 mg       | 30 mg               | −                   | −      | Tablet |
| 2017S_FG_6 | 600 mg       | 36 mg               | Zinc 3.6 mg, Iron 4.5 mg, Manganese 0.9 mg, Copper 0.24 mg | −      | Tablet |
| 2017S_FG_7 | 500 mg       | 36 mg               | Zinc 3.57 mg, Iron 4.56 mg, Manganese 1.29 mg, Copper 0.344 mg | −      | Tablet |

α-TE, alpha-tocopherol equivalent; NE, niacin equivalent.

All solutions used in this study were prepared freshly before use except for the standard solutions.

Preparation of analytical samples

**Influence of mineral supplements on quercetin recovery:** Samples for evaluation of the influence of each mineral supplement on quercetin recovery were prepared as follows. Solutions of 8 mL diluent and 1 mL of 10 mg/mL quercetin hydrate were added into 10 mL conical tubes, and 1 mL of each 10 mg/mL mineral supplement solution was added into each individual tubes.

Samples for evaluation of the influence of iron and copper supplement concentrations on quercetin recovery were prepared as follows. Solutions of 8 mL diluent and 1 mL of 10 mg/mL quercetin hydrate were added into 10 mL conical tubes, before iron (III) chloride, iron (II) fumarate, or copper (II) sulfate solution was added to final concentrations of 0.05, 0.25, 0.5, and 1 mg/mL. Further diluent was added to a total volume of 10 mL.

As a control, 1 mg/mL quercetin hydrate containing diluent was prepared. Assuming the quercetin recovery from the control was 100%, the relative recovery of each sample containing the mineral supplements were determined.

**Suppression of quercetin oxidation due to addition of antioxidants in the diluent:** Samples for evaluation of the suppressive effects of each artificial antioxidant on quercetin oxidation were prepared as follows. Solutions of 8 mL diluent and 1 mL of 10 mg/mL quercetin hydrate were added into 10 mL conical tubes, and EDTA, TBHQ, BHA, BHT, or PG solution were added to final concentrations of 2 and 4 mg/mL. Iron (III) chloride was added to a concentration of 0.5 mg/mL, and was topped up with further diluent to a total volume to 10 mL.

Samples for evaluating the suppressive effect of TBHQ concentration on quercetin oxidation were prepared as follows. Solutions of 4 mL diluent and 1 mL of 1 mg/mL quercetin hydrate were added into 10 mL conical tubes. 50 mg/mL TBHQ solution was added to final concentrations of 5, 10, 15, and 20 mg/mL. Solutions of 1 mL of 10 mg/mL iron (III) chloride, 10 mg/mL iron (II) fumarate, 10 mg/mL copper (II) sulfate, or 1 mg/mL copper (II) sulfate were then added, and topped up with further diluent to a total volume of 10 mL.

As a control, 1 mg/mL quercetin hydrate and 0.5 mg/mL iron (III) chloride containing diluent was prepared. Assuming the quercetin recovery from 1 mg/mL quercetin hydrate containing the diluent used in above was 100%, we were able to determine the relative recoveries of the samples and control.

Each prepared sample was placed in a water bath at 90 °C for 60 min for hydrolysis, and then cooled to an ambient temperature. A portion of the hydrolyzed solution was diluted 10-fold with methanol, filtered through 0.45
Fig. 1. Reduced recovery of quercetin by (A) mineral supplements and (B) concentration of iron (II) fumarate, iron (III) chloride, and copper (II) sulfate. The described concentration is the concentration in the diluent. All values shown are the mean of three independent replicates, and the error bars are the mean±standard deviation. *Significantly lower than control at P<0.05.
(II) gluconate, or manganese (II) sulfate were not significantly different from the control. Whilst zinc (II) and manganese (II) had no effect on recovery, copper (II) and iron (III) reduced recovery significantly (P<0.05), presumably due to quercetin oxidation (Fig. 1A).

The effects of iron (III) chloride, iron (II) fumarate, and copper (II) sulfate on quercetin recovery were next investigated by varying the concentrations of these supplements from 0.05 to 1 mg/mL; the greater the amount of supplemented mineral, the greater the reduction in quercetin recovery (Fig. 1B).

Balcerzak et al. (21) developed a selective ultraviolet (UV)-spectrophotometric method for determination of iron (III) in iron (II)-containing pharmaceutical products. This method is based on the redox reactions occurring between iron (III) ions and quercetin. The authors reported that iron (II) did not react with quercetin under the experimental conditions used [aqueous : methanolic (3:2) solutions, 0.3 M HCl]. Moreover, that the equilibrium in both complexation and the redox reactions between iron (III) and quercetin depend on the hydrochloric acid concentration, reaction time, and temperature. Lower acid concentrations were favorable for formation of the iron (III)-quercetin complex. An increase in HCl concentration in solutions containing the complex shifts the equilibrium towards the redox process, leading to quantitative formation of the final oxidized form of quercetin. The optimum HCl concentrations for formation of the complex and product in the redox reaction are 0.03 M and 0.3 M, respectively. Furthermore, redox reactions can be significantly accelerated by heating. The HCl concentration in the diluent used in this study was 1.2 M, which decreased to 0.24 M when diluted 5-fold with methanol per the flavonol glycoside determination method of the MFDS. Compared with those previously reported (21), the concentrations in the present study represent conditions under which redox reactions are more favorable than chelation. Liu and Guo (23) reported that the stability of quercetin-divalent metal ion complexes decreased in the following order: Cu (II)>Ni (II)>Co (II)>Fe (II)>Zn (II). At a flavonoid : metal stoichiometry ratio of 2:1, complexes formed between quercetin and metal ions [Fe (II), Ni (II), Co (II), and Zn (II)] had similar fragmentation mechanisms; whereas Cu (II) showed a different fragmentation mechanism due to concurrent oxidation, which was partially because Cu (II) has stronger oxidative activity and quercetin is easier to oxidize under acidic conditions. Fernandez et al. (25) suggested that the higher yield generated in redox reactions with copper rather than iron is consistent with the lower redox potential of Cu (II)/Cu (I) compared with that of Fe (III)/Fe (II).

The reduced recovery of quercetin in the presence of iron (II) fumarate and iron (II) sulfate divalent iron, is discussed in the subsequent results.

Suppression of quercetin oxidation due to addition of antioxidants to the diluent

Among the tested antioxidants, quercetin recovery was highest when TBHQ was added to the diluent containing iron (III) chloride (Fig. 2A), whereby the higher the TBHQ concentration, the higher the quercetin recovery (Fig. 2B). While the quercetin recovery of the diluent without TBHQ was 0% (not detected), TBHQ-containing diluents exhibited recoveries of 92~102% of the control.

Hertog et al. (26), Merken and Beecher (27), Toku et al. (28), and Kwak et al. (29) also used TBHQ in studies of vegetable and fruit flavonoids. The concentrations used in these studies ranged from 0.4 to 2 mg/mL, which are much lower than those used in the present study. Our results show that a larger amount of TBHQ is required to inhibit oxidation reactions in samples containing high

---

**Fig. 2.** Enhanced recovery of quercetin by (A) antioxidants and (B) concentration of tert-butyl hydroquinone (TBHQ). The described concentration is the concentration in the diluent. PG, propyl gallate; EDTA, ethylenediaminetetraacetic acid; BHA, butylated hydroxyanisole. All values shown are the mean of three independent replicates, and the error bars are the mean±standard deviation.
The concentrations of quercetin and mineral supplements used in quercetin recovery testing were determined with reference to their concentrations in GBE-containing HFFs manufactured and sold in Korea. The contents per serving size in 108 GBE products registered with the MFDS are 28~36 mg flavonol glycosides, 3.63~6.70 mg iron, and 0.24~0.34 mg copper, if added. When these were analyzed using the MFDS testing method, the concentrations in the conventional diluent were 0.03~0.96 mg/mL quercetin (corrected using the conversion factor for flavonol glycoside to quercetin, assuming that only the quercetin aglycone was present), approximately 0.35~0.85 mg/mL iron (III) chloride or iron (II) fumarate, and 0.03~0.05 mg/mL copper (II) sulfate.

**Comparison of TBHQ-containing and conventional diluents**

The flavonol glycoside content in seven GBE-containing supplement products was measured over time. The flavonol glycoside content of the products containing no mineral supplements (2017S_FG_1, 2017S_FG_5), and of those containing zinc (II) supplement (2017S_FG_4), or zinc (II) and iron (II) supplements (2017S_FG_3), did not change over time. However, three products supplemented with copper (2017S_FG_2, 2017S_FG_6, and 2017S_FG_7) showed a decrease in total flavonol glycoside content over time (P<0.05) (Table 1 and Fig. 3).

![Fig. 3](image-url)  
*Fig. 3.* Change of total flavonol glycoside contents in the final test solution of *Ginkgo biloba* dietary supplement products during storage periods hydrolyzed by tert-butyl hydroquinone (TBHQ) added diluent and conventional diluent. Bar graphs indicate the amount of each flavonol aglycone which was hydrolyzed by conventional diluent. All values shown are the mean of three independent replicates, and the error bars are the mean±standard deviation.
The reduction in flavonol glycoside content varied depending on the product. Relative to the claim on the label, the total content in 2017S_FG_2 decreased from 105.8% (immediately after preparing the test solution) to 75.5% after 1 day, and to 53.7% after day 2. This decrease was due to a decrease in the amount of quercetin; the effect of kaempferol or isorhamnetin was negligible. However, when 20 mg/mL of TBHQ was added to the diluent, the amount of quercetin remained relatively constant: 112.0% immediately after preparation, 109.1% after 1 day, and 103.1% after day 2. The other two samples containing copper, 2017S_FG_6 and 2017S_FG_7, showed similar results to 2017S_FG_2.

We did not detect any changes in the amount of kaempferol. The amount of quercetin in the solution decreased due to rapid oxidization under test conditions, whereas kaempferol was stable. Fernandez et al. (25) reported that quercetin has a greater reducing ability than kaempferol.

In previous studies, quercetin recovery was reduced due to iron (II) fumarate and iron (II) sulfate. However, the results of our analysis of 2017S_FG_3, a product containing iron (II) fumarate, showed no changes in the amount of quercetin over time, even without TBHQ addition. It therefore appears that iron (II) fumarate is not directly involved in quercetin oxidation. An explanation for the decrease in quercetin recovery in previous studies using iron (II) fumarate may be due to oxidation of iron (II) to iron (III) over the course of the experiment, or the presence of a trivalent iron in the reagent. According to the manufacturer’s certificate of analysis, the reagent contains 0.5 % iron (III).

Jungbluth et al. (30) reported that quercetin may be oxidized in the presence of Cu (II) or Fe (III) in aqueous media, but Fe (II) causes no immediate change in the UV/Vis spectra of the flavonoids. The authors suggested that the presence of iron in either oxidation state may lead to transformation of flavonols due to possible oxidation of Fe (II) to Fe (III) through molecular oxygen.

**Change in total flavonol glycoside content in GBE-containing dietary supplement products based on hydrolysis duration and diluent**

The total flavonol glycoside content in 2017S_FG_2 was measured after different durations of hydrolysis. When the conventional diluent was used, the amount of quercetin began to decrease at 60 min, and showed a significant difference from 75 min \((P<0.05)\) (Fig. 4). Therefore, in the analysis of copper-supplemented products, the flavonol glycoside content may be underestimated due to prolonged hydrolysis. However, when TBHQ was added to the diluent, the flavonol glycoside content was consistent regardless of the duration of hydrolysis.

Hertog et al. (26) optimized a quantitative HPLC-based method for determination of flavonoid aglycones in vegetables and fruits following acid hydrolysis of glycosides. The authors reported that increasing the acid concentration and reaction time of the acid hydrolysis led to significant quercetin degradation in sample solutions. However, flavonol degradation was not observed in the standard solutions treated under identical conditions. Therefore, whether the presence of some unknown compounds in the sample matrix may have accelerated degradation of flavonoids should be considered. Vegetables and fruits naturally contain trace amounts of iron and copper; these metals could be the compounds accelerating degradation of flavonoids.

GBE-containing products supplemented with iron (III) were not available. However, iron (III) supplements, such as iron (III) chloride, have also been approved for iron fortification. In products containing iron (III), quercetin oxidation can occur during analysis, similar to in copper-containing products.

Fig. 5 shows chromatograms of sample No. 2017S_FG_7, obtained 2 days after preparation of test solutions. The peak elution at 5.13 min is presumed to be a product of quercetin oxidation, considering that the peak intensity was inversely proportional to the decrease in quercetin, and that the UV spectrum was similar to the spectrum of the oxidation products of quercetin (21,22). TBHQ eluted at approximately 9.53 min and was not detected at the aglycone assay wavelength of 370 nm, but was detected instead at 291 nm. TBHQ was also completely separated from quercetin \((Rs=8)\), the closest peak, and,
The effects of eight mineral supplements commonly used in dietary supplement foods on the recovery of quercetin were investigated. Zn (II), Mn (II), and Fe (II) supplements did not affect quercetin recovery, but Cu (II) and Fe (III) supplements significantly reduced the recovery rate in a dose-dependent manner (P<0.05). This result may be due to copper and iron ions reacting with quercetin to accelerate its oxidation during analysis. As the quercetin is oxidized and degraded, the total flavonol glycoside content of GBE dietary supplement products may be measured as less than the amount actually present or that labelled on the product. As a result, an adequate product can be misjudged as a violated product with inadequate flavonol glycoside content.

Quercetin oxidation could be inhibited by adding an antioxidant during recovery. Of a total of four synthetic antioxidants, TBHQ showed the greatest increase in quercetin recovery, acting in a dose-dependent manner. The flavonol glycoside contents of seven commercially available GBE-containing dietary supplement foods were analyzed using a conventional diluent and a diluent containing 20 mg/mL TBHQ. The amount of quercetin recovered from three products supplemented with copper decreased with an increase in hydrolysis duration, and the duration of the final test solution state using the conventional diluent; whereas the TBHQ-containing diluent resulted in a consistent quercetin yield (P<0.05). A simple modification of the conventional flavonol glycoside determination method, such as addition of TBHQ to the diluent, can improve the accuracy and reproducibility of flavonol glycoside content analysis in GBE-containing dietary products supplemented with metals.

**AUTHOR DISCLOSURE STATEMENT**

The authors declare no conflict of interest.

**REFERENCES**

1. Zhao Y, Paule J, Fu C, Koch MA. 2010. Out of China: distribution history of *Ginkgo biloba* L.. *Taxon* 59: 495-504.
2. Singh B, Kaur P, Gopichand, Singh RD, Ahuja PS. 2008. Biology and chemistry of *Ginkgo biloba*. *Fitoterapia* 79: 401-418.
3. IARC Monographs Working Group. 2013. *Some drugs and herbal products: IARC monographs on the evaluation of carcinogenic risks to humans*. WHO Press, Geneva, Switzerland. Vol 108, p 91-116.
4. Rai GS, Shovlin C, Wesnes KA. 1991. A double-blind, placebo controlled study of *Ginkgo biloba* extract (‘tanakan’) in elderly outpatients with mild to moderate memory impairment. *Curr Med Res Opin* 12: 350-355.
5. Mouren X, Caillard P, Schwartz F. 1994. Study of the antiischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcPo2 determination. *Angiology* 45: 413-417.
6. Hopfenmüller W. 1994. Evidence for a therapeutic effect of *Ginkgo biloba* special extract. Meta-analysis of 11 clinical studies in patients with cerebrovascular insufficiency in old age. *Arzneimittel forschung* 44: 1005-1013.
7. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. 1997. A placebo-controlled, double-blind, randomized trial of an extract of *Ginkgo biloba* for dementia. *North American EgB Study Group*. *JAMA* 278: 1327-1332.
8. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R. 1997. Proof of efficacy of the *Ginkgo biloba* special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. *Phytotherapy* 152: 353-361.

9. Wesnes KA, Ward T, McGinty A, Petrini O. 2000. The memory enhancing effects of a *Ginkgo biloba*/Panax ginseng combination in healthy middle-aged volunteers. *Psychopharmacology* 152: 3-13.

10. Snitz BE, O’Meara ES, Carlson MC, Arnold AM, Ives DG, Rapp SR, Sink KM, Lopez OL, Saxton J, Yoon MK, Kim SJ. 2016. Variation of quercetin glycoside derivatives in three onion (*Allium cepa* L.) varieties. *Saudi J Biol Sci* 24: 1387-1391.

11. Jungbluth G, Rühling I, Ternes W. 2000. Oxidation of flavonols with Cu(II), Fe(II) and Fe(III) in aqueous media. *J Chem Soc Perkin Trans 2* 29: 1946-1952.

12. Merken HM, Beecher GR. 2000. Liquid chromatographic method for the separation and quantification of prominent flavonoid aglycones. *J Chromatogr A* 897: 177-184.

13. Tokusoğlu Ö, Ünal MC, Yıldırım Z. 2003. HPLC-UV and GC-MS characterization of the flavonol aglycon quercetin, kaempferol and myricetin in tomato pastes and other tomato-based products. *Acta Chromatogr 13*: 196-207.

14. Doubs A. 2005. 2006 USP 29 NF 24 United State pharmacopoeia the national formulary, the (Asian edition) (hb) 2005. Afzal Rauf News Agency, Karachi, Pakistan. p 2334-2335.

15. MFDS. Domestic Health/Functional Foods. https://www.foodsafetykorea.go.kr/portal/healthyfoodlife/searchHomeHF.do (accessed Jan 2017).

16. Symonowicz M, Kolanek M. 2012. Flavonoids and their properties to form chelate complexes. *Biotechnol Food Sci 76*: 35-41.

17. Balcerzak M, Tyburska A, Świerccka-Füchsel E. 2008. Selective determination of Fe(III) in Fe(II) samples by UV-spectrophotometry with the aid of quercetin and morin. *Acta Pharm 58*: 327-334.

18. EDQM Council of Europe. 2013. *European Phamacopoeia (Ph. Eur.)*. 8th ed. Council of Europe, Strasbourg, France. p 1259-1261.